Physiologically based pharmacokinetics (PBPK)

References

• Aarons, L. (2005). Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed. Br J Clin Pharmacol 60:6:581–583.
   PubMed Web of Science ®Google Scholar
• Agoram, B., Woltosz, W.S., Bolger, M.B. (2001). Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 50:S41–67.
   PubMed Web of Science ®Google Scholar
• Arundel, P.A. (1997). A multi-compartmental model generally applicable to physiologically-based pharmacokinetics. Poster presentation during the third IFAC symposium “Modeling and Control in Biomathematical Systems.” Warwick, UK.
   Google Scholar
• Bachman, K. (1989). Predicting toxicokinetic parameters in humans from toxicokinetic data acquired from three small mammalian species. J Appl Toxicol 9:331–338.
   PubMed Web of Science ®Google Scholar
• Ballard, P., Leahy, D.E., Rowland, M. (2000). Prediction of in vivo tissue distribution from in vitro data 1. Experiments with markers of aqueous spaces. Pharm Res. 17:660–3.
   PubMed Web of Science ®Google Scholar
• Björkman, S. (2004). Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol 59:691–704.
   Web of Science ®Google Scholar
• Boxenbaum, H. (1982). Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10:201–207.
   PubMedGoogle Scholar
• Brightman, F.A., Leahy, D.E., Searle, G.E., Thomas, S. (2006a). Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in rat plasma. Drug Metab Dispos 34:84–93.
   PubMed Web of Science ®Google Scholar
• Brightman, F.A., Leahy, D.E., Searle, G.E., Thomas, S. (2006b). Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in human plasma. Drug Metab Dispos 34:94–101.
   PubMed Web of Science ®Google Scholar
• Brown, R.P., Delp, M.D., Lindstedt, S.L., Rhomberg, L.R., Beliles, R.P. (1997). Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Indust Health 13:4:407–484.
   PubMed Web of Science ®Google Scholar
• Chappell, W. R. and Mordenti, J. (1989). The use of interspecies scaling in toxicokinetics. In: Yacobi, A., Skelly, J.P., Batra, V.K. (Eds.), Toxicokinetics and New Drug Development (pp 42–96 ). New York: Pergamon Press.
   Google Scholar
• Chappell, W.R., Mordenti, J. (1991). Extrapolation of toxicological and pharmacological data from animals to humans. Adv Drug Res 20:1–116.
   Google Scholar
• Chen, H.G., Gross, J.F. (1979). Estimation of tissue-to-plasma partition coefficients used in physiological pharmacokinetic models. J Pharmacokinet Biopharm 7:117–125.
   PubMedGoogle Scholar
• Chiu, W.A., Barton, H.A., DeWoskin, R.S., Schlosser, P., Thompson, C.M., Sonawane, B., et al. (2006). Evaluation of physiologically based pharmacokinetic models for use in risk assessment. J Appl Toxicol 27:218–37.
   Web of Science ®Google Scholar
• Clewell, H.J., Andersen, M.E., Wills, R.J., Latriano, L. (1997). A physiologically based pharmacokinetic model for retinoic acid and its metabolites. J Am Acad Dermatol 36:77–85.
   PubMed Web of Science ®Google Scholar
• Clewell, H.J., Gentry, P.R., Gearhart, J.M., Covington, T.R., Banton, M.I., Andersen, M.E. (2001). Development of a physiologically based pharmacokinetic model of isopropanol and its metabolite acetone. Toxicol Sci 63:160–172.
   PubMed Web of Science ®Google Scholar
• Daniel, W.A., Wojcikowski, J. (1997). Interactions between promazine and antidepressants at the level of cellular distribution. Pharmacol Toxicol. 81:259–64.
   PubMedGoogle Scholar
• De Buck S.S., Mackie, C.E. (2007c). Physiologically based approaches towards the prediction of pharmacokinetics: in vitro–in vivo extrapolation. Expert Opin Drug Metab Toxicol 3:865–878.
   PubMed Web of Science ®Google Scholar
• De Buck S.S., Sinha, V.K., Fenu, L.A., Gilissen, R.A., Mackie, C.E., Nijsen, M.J. (2007a). The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools. Drug Metab Dispos 35:649–659.
   PubMed Web of Science ®Google Scholar
• De Buck S.S., Sinha, V.K., Fenu, L.A., Nijsen, M.J., Mackie, C.E., Gilissen, R.A. (2007b). Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 35:1766–1780.
   PubMed Web of Science ®Google Scholar
• Dedrick, R.L. (1973). Animal scale-up. J Pharmacokinet Biopharm 1:435–461.
   PubMedGoogle Scholar
• Dedrick, R.L., Bischoff, B.K. (1968). Pharmacokinetics in application of the artificial. Chem Eng Progr Symp Ser 64:32–44
   Google Scholar
• Edginton, A.N., Schmitt, W., Willmann, S. (2006). Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet 45:1013–1034.
   PubMed Web of Science ®Google Scholar
• Edginton, A.N., Theil, F-P., Schmitt, W., Willmann, S. (2008). Whole body physiologically based pharmacokinetic models: their use in clinical drug development. Exp Opin Drug Metab Toxicol 4:1143–1152.
   PubMed Web of Science ®Google Scholar
• Ellmerer, M., Schaupp, L., Brunner, G.A., Sendlhofer, G., Wutte, A., Wach, P., et al. (2000). Measurement of interstitial albumin in human skeletal muscle and adipose tissue by open-flow microperfusion. Am J Physiol Endocrinol Metab 278:E352–E356.
   PubMed Web of Science ®Google Scholar
• Feng, M.R., Lou, X., Brown, R.R., Hutchaleelaha, A. (2000). Allometric pharmacokinetic scaling: towards the prediction of human oral pharmacokinetics. Pharm Res (NY) 17:410–418.
   PubMed Web of Science ®Google Scholar
• Gabrielsson, J., Bondesson, U. (1987). Constant-rate infusion of nicotine and cotinine. I. A physiological pharmacokinetic analysis of the cotinine disposition, and effects on clearance and distribution in the rat. J Pharmacokinet Biopharm 15:583–99.
   PubMedGoogle Scholar
• Gallo, J.M., Lam, F.C., Perrier, D.G. (1987). Area method for the estimation of partition coefficients for physiological pharmacokinetic models. J Pharmacokinet Biopharm 15:271–280.
   PubMedGoogle Scholar
• Gerlowski, L.E., Jain, R.K. (1983). Physiologically based pharmacokinetic modeling: principles and applications. J Pharm Sci 72:1103–1127.
   PubMed Web of Science ®Google Scholar
• Germani, M., Crivori, P., Rocchetti, M., Burton, P.S., Wilson, A.G., Smith, M.E., et al. (2007). Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study. Eur J Pharm Sci 31:190–201.
   PubMed Web of Science ®Google Scholar
• Grime, K.H., Bird, J., Ferguson, D., Riley, R.J. (2009). Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. Euro J Pharm Sci. 36(2–3):175–91.
   Web of Science ®Google Scholar
• Haddad, S., Pelekis, M., Krishnan, K. (1996). A methodology for solving physiologically based pharmacokinetic models without the use of simulation softwares. Toxicol Lett 85:113–126.
   PubMed Web of Science ®Google Scholar
• Houston, J.B. (1994). Utility of in vitro drug metabolizing data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469–1479.
   PubMed Web of Science ®Google Scholar
• Howgate, E.M., Rowland-Yeo, K., Proctor, N.J., Tucker, G.T., Rostami-Hodjegan, A. (2006). Prediction of in vivo drug clearance from in vitro data. I: impact of interindividual variability. Xenobiotica. 36:473–97.
   PubMed Web of Science ®Google Scholar
• Inoue, S., Howgate, E.M., Rowland-Yeo, K., Shimada, T., Yamazaki, H., Tucker, G.T., et al. (2006). Prediction of in vivo drug clearance from in vitro data. 2: Potential interethnic differences. Xenobiotica. 36:499–513.
   PubMed Web of Science ®Google Scholar
• Ito, K., Iwatsubo, T., Kanamitsu, S., Nakajima, Y., Sugiyama, Y. (1998). Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol 38:461–99.
   PubMed Web of Science ®Google Scholar
• Ito, K., Ogihara, K., Kanamitsu, S-I., Itoh, T. (2003). Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 31:945–954.
   PubMed Web of Science ®Google Scholar
• Jamei, M., Marciniak, S., Feng, K., Barnett, A., Tucker, G., Rostami- Hodjegan, A. (2009). The Simcyp® population-based ADME simulator. Exp Opin Drug Metab Toxicol Feb 6. [early online].
   PubMed Web of Science ®Google Scholar
• Johnson, T.N., Rostami-Hodjegan, A., Tucker, J.T. (2006). Prediction of the clearance of eleven drugs and associated variability in neonates, infants, and children. Clin Pharmacokinet 45:931–956.
   PubMed Web of Science ®Google Scholar
• Jones, H.M., Parrott, N., Jorga, K., Lavé, T. (2006a). A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 45:511–542.
   PubMed Web of Science ®Google Scholar
• Jones, H.M., Parrott, N., Ohlenbusch, G., Lavé, T. (2006b). Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modeling. Clin Pharmacokinet 45:1213–1226.
   PubMed Web of Science ®Google Scholar
• Kanamitsu, S., Ito, K., Sugiyama, Y. (2000). Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm Res 17:336–43.
   PubMed Web of Science ®Google Scholar
• Kato, M., Shitara, Y., Sato, H., Yoshisue, K., Hirano, M., Ikeda, T., et al. (2008). The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling. Pharm Res 25:1891–901.
   PubMed Web of Science ®Google Scholar
• Kawai, R., Lemaire, M., Steimer, J.L., Bruelisauer, A., Niederberger, W., Rowland, M. (1994). Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125. J Pharmacokinet Biopharm 22:327–65.
   PubMedGoogle Scholar
• Kawai, R., Mathew, D., Tanaka, C., Rowland, M. (1998). Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human. J Pharmacol Exp Ther 287:457–68.
   PubMed Web of Science ®Google Scholar
• Lavé, T., Coassolo, P., Reigner, B. (1999). Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro–in vivo correlations. Clin Pharmacokinet 36:211–31.
   PubMed Web of Science ®Google Scholar
• Lavé, T.H., Dupin, S., Schmitt, C., Chou, R.C., Jaeck, D., Coassolo, P.H. (1997). Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. J Pharm Sci 86:584–90.
   PubMed Web of Science ®Google Scholar
• Lavé, T., Parrott, N., Grimm, H.P., Fleury, A., Reddy, M. (2007). The fate and safety evaluation of foreign compounds in biological systems. Xenobiotica 37:1295–1310.
   PubMed Web of Science ®Google Scholar
• Lavé, T., Portmann, R., Schenker, G., Gianni, A., Guenzi, A., Girometta, M.A., et al. (1999). Interspecies pharmacokinetic comparison and allometric scaling of napsagatran, a low molecular weight thrombin inhibitor. J Pharm Pharmacol 49:178–183.
   Google Scholar
• Leo, A., Hansch, C., Elkins, D. (1971). Partition coefficients and their uses. Chem Rev 71:525–615.
   Web of Science ®Google Scholar
• Leung, H.W., Paustenbach, D.J. (1995). Physiologically based pharmacokinetic and pharmacodynamic modeling in health risk assessment and characterization of hazardous substances. Toxicol Lett 79:55–65.
   PubMed Web of Science ®Google Scholar
• Leusch, A., Troger, W., Greishel, A., Roth, W. (2000). Pharmacokinetics of the M1-agonist talsaclidine in mouse, rat, rabbit, and monkey, and extrapolation to man. Xenobiotica 30:797–813.
   PubMed Web of Science ®Google Scholar
• Lin, J.H., Sugiyama, Y., Awazu, S., Hanano, M. (1982). In vitro and in vivo evaluation of the tissue to blood partition coefficient for physiological pharmacokinetic models. J Pharmacokinet Biopharm. 10:637–47.
   PubMedGoogle Scholar
• Lin, J.H. (1998). Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab Dispos 26:1202–12.
   PubMed Web of Science ®Google Scholar
• Lüpfert, C., Reichel, A. (2005). Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery. Chem Biodivers 2:1462–86.
   PubMed Web of Science ®Google Scholar
• Luttringer, O., Theil, F.P., Poulin, P., Schmitt-Hoffmann, A.H., Guentert, T.W., Lavé, T. (2003). Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans. J Pharm Sci 92:1990–2007.
   PubMed Web of Science ®Google Scholar
• MacDonald, A.J., Parrott, N., Jones, H., Lavé, T. (2004). Modelling and simulation of pharmacokinetic and pharmacodynamic systems—approaches in drug discovery. The Chemical Theatre of Biological Systems. May 24–28th, Bozen, Italy.
   Google Scholar
• Mahmood, I. (1998a). Interspecies scaling: predicting volumes, mean residence time, and elimination half-life: some suggestions. J Pharm Sci 87:527–529.
   PubMed Web of Science ®Google Scholar
• Mahmood, I. (1998b). Interspecies scaling of renally secreted drugs. Life Sci 63:2365–2371.
   PubMed Web of Science ®Google Scholar
• Mahmood, I. (2000a). Can absolute oral bioavailability in humans be predicted from animals?: a comparison of allometry and different indirect methods. Drug Metab Drug Interact 16:143–155.
   PubMedGoogle Scholar
• Mahmood, I. (2000b). Interspecies scaling: role of protein binding in the prediction of clerance from animals to humans. J Clin Pharmacol 40:1439–1446.
   PubMed Web of Science ®Google Scholar
• Mahmood, I. (2002). Prediction of clearance in humans from in vitro human liver microsomes and allometric scaling. A comparative study of the two approaches. Drug Merab Drug Interact 19:49–64.
   PubMedGoogle Scholar
• Mahmood, I. (2005a). Interspecies scaling of clearance. In: Interspecies Pharmacokinetic Scaling: Principles and Application of Allometric Scaling. Rockville, Maryland, USA: Pine House.
   Google Scholar
• Mahmood, I. (2005b). Interspecies scaling of drugs cleared by the kidneys and the bile. In: Interspecies Pharmacokinetic Scaling: Principles and Application of Allometric Scaling. Rockville, Maryland, USA: Pine House.
   Google Scholar
• Mahmood, I. (2005c). Interspecies scaling of volumes of distribution. In: Interspecies Pharmacokinetic Scaling: Principles and Application of Allometric Scaling. Rockville, Maryland, USA: Pine House.
   Google Scholar
• Mahmood, I., Balian, J.D. (1996a). Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. J Pharm Sci 85:411–414.
   PubMed Web of Science ®Google Scholar
• Mahmood, I., Balian, J.D. (1996b). Predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887–895.
   PubMed Web of Science ®Google Scholar
• Mahmood, I., Sahajwalla, C. (2002). Interspecies scaling of biliary excreted drugs. J Pharm Sci 91:1908–1914.
   PubMed Web of Science ®Google Scholar
• McGinnity, D.F., Collington, J., Austin, R.P., Riley, R.J. (2007). Evaluation of human pharmacokinetics, therapeutic dose, and exposure predictions using marketed oral drugs. Curr Drug Metab 8:463–479.
   PubMed Web of Science ®Google Scholar
• Moghadamnia, A.A., Rostami-Hodjegan, A., Abdul-Manap, R., Wright, C.E., Morice, A.H., Tucker, G.T. (2003). Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition. Br J Clin Pharmacol 56:57–67.
   PubMed Web of Science ®Google Scholar
• Mordenti, J. (1986). Man versus beast. J Pharm Sci 75:1028–1040.
   PubMed Web of Science ®Google Scholar
• Nagilla, R., Ward, K. (2004). A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog, and monkey to humans. J Pharm Sci 93:2522–2534.
   PubMed Web of Science ®Google Scholar
• Nasu, R., Kumagai, Y., Kogetsu, H., Tsujimoto, M., Ohtani, H., Sawada, Y. (2005). Physiologically based pharmacokinetic model for pralmorelin hydrochloride in rats. Drug Metab Dispos 33:1488–94.
   PubMed Web of Science ®Google Scholar
• Nestorov, I. (2003). Whole body pharmacokinetic models. Clin Pharmacokinet 42:883–908.
   PubMed Web of Science ®Google Scholar
• Obach, R.S., Baxter, J.G., Liston, T.E., Silber, B.M., Jones, C., Macintyre, F., et al. (1997). The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism. J Pharmacol Exp Ther 283:46–58.
   PubMed Web of Science ®Google Scholar
• Parrott, N., Jones, H., Paquereau, N., Lavé, T. (2005b). Application of full physiological models for pharmaceutical drug selection and extrapolation of pharmacokinetics to man. Basic Clin Pharm Toxicol 96:193–199.
   PubMed Web of Science ®Google Scholar
• Parrott, N., Lavé, T. (2002). Prediction of intestinal absorption: comparative assessment of GASTROPLUS and IDEA. Eur J Pharm Sci 17:51–61.
   PubMed Web of Science ®Google Scholar
• Parrott, N., Paquereau, N., Coassolo, P., Lavé, T. (2005a). An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery. J Pharm Sci. 94:2327–2343.
   PubMed Web of Science ®Google Scholar
• Peters, S.A. (2008). Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis. Clin Pharmacokinet 47:261–75.
   PubMed Web of Science ®Google Scholar
• Ploeger, B., Mensinga, T., Sips, A., Meulenbelt, J., DeJongh, J. (2000). A human physiologically based model for glycyrrhzic acid, a compound subject to presystemic metabolism and enterohepatic cycling. Pharm Res 17:1516–25.
   PubMed Web of Science ®Google Scholar
• Poggesi, I. (2004). Predicting human pharmacokinetics from preclinical data. Curr Opin Drug Discov Devel 7:100–111.
   PubMed Web of Science ®Google Scholar
• Poulin, P., Schoenlein, K., Theil, F.P. (2001). Prediction of adipose tissue:plasma partition coefficients for structurally unrelated drugs. J Pharm Sci 90:436–47.
   PubMed Web of Science ®Google Scholar
• Poulin, P., Theil, F.P. (2000). A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically based pharmacokinetic models in drug discovery. J Pharm Sci 89:16–35.
   PubMed Web of Science ®Google Scholar
• Poulin, P., Theil, F.P. (2002a). Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 91:129–56.
   PubMed Web of Science ®Google Scholar
• Poulin, P., Theil, F.P. (2002b). Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci 91:1358–70.
   PubMed Web of Science ®Google Scholar
• Rodgers, T., Leahy, D., Rowland, M. (2005). Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 94:1259–1276. Erratum in: J Pharm Sci (2007) 96:3151–3152.
   PubMed Web of Science ®Google Scholar
• Rodgers, T., Rowland, M. (2006). Physiologically based phar macokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals, and zwitterions. J Pharm Sci 95:1238–1257. Erratum in: J Pharm Sci (2007) 96:3153–3154.
   PubMed Web of Science ®Google Scholar
• Rodgers, T., Rowland, M. (2007). Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res 24:918–933.
   PubMed Web of Science ®Google Scholar
• Rostami-Hodjegan, A., Tucker, G.T. (2007). Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev. Drug Discov. 6:140–8.
   PubMed Web of Science ®Google Scholar
• Rowland, M., Balant, L., Peck, C. (2004). Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29–30, 2002). AAPS Journal 6:1–12.
   PubMedGoogle Scholar
• Sanwald-Ducray, P., Dow, J. (1997). Prediction of the pharmacokinetic parameters of reduced-dolasetron in man using in vitro–in vivo and interspecies allometric scaling. Xenobiotica 27:189–201.
   PubMed Web of Science ®Google Scholar
• Sawada, Y., Hanano, M., Sugiyama, Y., Harashima, H., Iga, T. (1984). Prediction of the volumes of distribution of basic drugs in humans based on data from animals. J Pharmacokinet Biopharm 12:587–596.
   PubMedGoogle Scholar
• Tanaka, C., Kawai, R., Rowland, M. (2000). Dose-dependent pharmacokinetics of cyclosporin A in rats: events in tissues. Drug Metab Dispos 28:582–589.
   PubMed Web of Science ®Google Scholar
• Tang, H., Mayersohn, M. (2005). A novel model for prediction of human drug clearance by allometric scaling. Drug Metab Dispos 33:1297–1303.
   PubMed Web of Science ®Google Scholar
• Theil, F.P., Guentert, T.W., Haddad, S., Poulin, P. (2003). Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol Lett 138:29–49.
   PubMed Web of Science ®Google Scholar
• Tucker, G.T., Houston, J.B., Huang, S.M. (2001). Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential—toward a consensus. Clin. Pharmacol Ther 70:103–114.
   PubMedGoogle Scholar
• Wajima, T., Fukumura, K., Yano, Y., Oguma, T. (2002). Prediction of human clearance from animal data and molecular structural parameters using multivariate regression analysis. J Pharm Sci 91:2489–2499.
   PubMed Web of Science ®Google Scholar
• Weiss, M., Sziegoleit, W., Förster, W. (1977). Dependence of pharmacokinetic parameters on the body weight. Int J Clin Pharmacol Biopharm 15:572–575.
   PubMedGoogle Scholar
• Willmann, S., Lippert, J., Schmitt, W. (2005). From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools. Exp Opin Drug Metab Toxicol 1:159–168.
   PubMedGoogle Scholar
• Willmann, S., Lippert, J., Sevestre, M., Solodenko, J., Fois, F., Schmitt, W. (2003). PK-Sim: a physiologically based pharmacokinetic “whole-body” model. Biosilico 1:121–124.
   Google Scholar
• Willmann, S., Schmitt, W., Keldenich, J., Lippert, J., Dressman, J.B. (2004). A physiological model for the estimation of the fraction dose absorbed in humans. J Med Chem 47:4022–4031.
   PubMed Web of Science ®Google Scholar
• Willmann, S., Schmitt, W., Stass, H., Ahr, G., Edginton, A.N. (2006). Pharmacologically based pharmacokinetic simulations of ciprofloxacin in obese and renally impaired individuals. Poster presentation at the 2006 EUFEPS annual meeting Dec. 2006 Basel, Switzerland.
   Google Scholar
• Yang, J.S., Rostami-Hodjegan, A., Tucker, G.T. (2001). Prediction of ketoconazole interaction with midazolam, alprazolam, and triazolam: Incorporating population variability. Br J Clin Pharmacol 2001, 52:472–3.
   Google Scholar
• Yu, L.X., Amidon, G.L. (1998). Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data. Eur J Pharm Biopharm 45:199–203.
   PubMed Web of Science ®Google Scholar
• Yu, L.X., Amidon, G.L. (1999). A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm 186:119–125.
   PubMed Web of Science ®Google Scholar
• Yu, L.X., Lipka, E., Crison, J.R., Amidon, G.L. (1996). Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv Drug Deliv Rev 19:359–376.
   PubMed Web of Science ®Google Scholar
• Zuegge, J., Schneider, G., Coassolo, P., Lavé, T. (2001). Prediction of hepatic metabolic clearance: comparison and assessment of prediction models. Clin Pharmacokinet 40:553–563.
   PubMed Web of Science ®Google Scholar